Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction | Cannabis Law Report | How to buy Skittles Moonrock online

Learn how to buy CBD Oil online. TOP QUALITY GRADE A++

Cannabyss Inc. is the best place online to buy top quality weed, cannabis, vape, marijuana and CBD products. Get your borderless orders delivered at the pickup spot with ease. Top Grade products for client satisfaction.

👉 Click here to Visit our shop! 🛒

Clearmind Medicine (NASDAQ: CMND) has announced the publication of a European patent (EP 4531826) for its psychedelic-based combination therapy targeting cocaine addiction. The therapy combines MEAI (5-methoxy-2-aminoindane) with N-Acylethanolamines, including Palmitoylethanolamide (PEA).

Preclinical trials conducted at Bar-Ilan University demonstrated that MEAI significantly reduced cocaine-seeking behavior in animals without affecting their response to natural rewards like sucrose. This suggests the treatment specifically targets drug-related compulsions rather than the general reward system.

The patent publication strengthens Clearmind’s intellectual property portfolio and complements similar filings in other markets. The development is part of an ongoing collaboration with SciSparc Ltd. (NASDAQ: SPRC) to explore combined MEAI and PEA-based technologies for treating central nervous system disorders.

Clearmind’s European patent publication strengthens IP protection for its psychedelic addiction therapy, critical for future commercialization potential.

This European patent publication represents a strategic IP milestone for Clearmind Medicine, expanding their global patent portfolio for their novel psychedelic-based addiction treatment. The patent specifically covers the combination of MEAI (5-methoxy-2-aminoindane) with N-Acylethanolamines like Palmitoylethanolamide (PEA) for treating cocaine addiction.

The territorial expansion to Europe is particularly significant as it complements existing filings in other markets, creating a more comprehensive global IP shield. For biotech companies, especially those working with novel compounds, robust patent protection across major markets is essential for preventing competitors from developing similar treatments and preserving future revenue opportunities.

What makes this patent scientifically intriguing is that it’s based on preclinical evidence showing MEAI reduced cocaine-seeking behavior without affecting responses to natural rewards. This selectivity suggests a mechanism that specifically targets drug cravings rather than broadly affecting reward pathways – a critical distinction for addiction treatments where preserving normal reward functions is desirable.

The ongoing collaboration with SciSparc Ltd. to explore combined applications of MEAI and PEA-based technologies indicates a strategy to develop a versatile treatment platform beyond just cocaine addiction, potentially addressing multiple CNS disorders.

While this patent publication doesn’t guarantee approval or commercial success, it’s a foundational element for Clearmind’s business strategy, creating potential barriers to entry for competitors and enhancing the company’s attractiveness for partnerships or acquisition. At this preclinical stage, the patent publication represents important progress in de-risking their intellectual property position, though significant clinical development work still lies ahead.